Embeda not completely tamper-proof, FDA advisers say

11/16/2008 | Boston Globe (tiered subscription model), The

An FDA advisory panel concluded Friday that the abuse-resistant properties of Embeda, a morphine-based drug candidate from Alpharma, may be effective only in some patients, offering a small advantage over other pain medications. Some advisers expressed concern that labeling the product as tamper-proof could mislead physicians and patients because Alpharma tested Embeda's resistance only as an oral treatment.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA